

REMARKS

At this time, Applicants wish to thank the Examiner for her time during the telephonic interview of January 28, 2003. During the telephonic interview, all pending rejections and objections were discussed. More specifically, the scope of the claims were discussed in view of the prior art. Applicants indicated that the scope of the claims covered cell lines having a given ATCC accession number and that these specific cell lines were not taught nor suggested by Dran et al. In view of this explanation, the Examiner indicated that the recitation of the ATCC accession number obviated the rejection.

Yet further during a second telephonic interview on January 30, 2003, Applicants discussed with the Examiner adding all four cell lines having ATCC accession numbers into the claims. Applicants indicated that shifting the scope of the claims from one cell line to four cell lines would result in no additional work or expense for the Examiner and if anything may reduce work by simplifying the issues, such as additional applications for each cell line. See MPEP § 819.01. The Examiner agreed to review claims of the four cell lines.

A. Status of Application

Claims 5, 7, 8 and 11 are pending in this application. Applicants have amended claims 5, 7, 8 and 11 without prejudice and acquiescence. Support for the amendments can be found in the original claims as filed and in the Specification on page 4, lines 19-24 and page 5, lines 1-5. Applicants have enclosed as Appendix A a marked version of the claims illustrating the amendments contained herein. For the convenience of the Examiner, Applicants have also enclosed in Appendix B a copy of all pending claims containing the amendments herein. Applicants assert that no new matter is added.

The issues outstanding in this application are as follows:

- The specification has been objected as the Office Action alleges that Applicants have not meet the conditions of the Budapest Treaty.
- Claims 5 and 11 have been rejected under 35 U.S.C. §103(c), which the Office Action alleges that the claimed subject matter is obvious by Dran et al.

Applicants respectfully traverse the outstanding rejections and objections, and

Applicants respectfully request reconsideration and withdrawal thereof in light of the amendments and remarks contained herein.

B. The Specification meets all requirements.

The Action has objected to the Specification because the Office Action alleges that Applicants have not meet the conditions of the Budapest Treaty. Applicants traverse.

Applicants enclose herewith notification from the ATCC indicating the deposition of the biological material. Yet further, in the previous response filed on September 18, 2002, Applicants amended the Specification to recite the name and address of the depository and the dates of the deposit. Still further, Applicants assert that all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent.

Thus, Applicants assert that all requirements have been meet under the Budapest Treaty and under 37 CFR 1.808 and respectfully request withdrawal of the objection.

C. Claims 5 and 11 are not anticipated.

Claims 5 and 11 have been rejected under U.S.C. § 103(c), which the Office Action alleges that the claimed subject matter is obvious by Duran et al. Applicants respectfully traverse.

Applicants assert that there is a distinct difference between a primary cell culture and the cell line of the present invention. The primary cell culture of Dran et al., has a lifespan of about two weeks. The cell lines of the present invention are immortal.

However, in order to advance the prosecution of the present application, Applicants have amended claims 5 and 11 to recite the ATCC accession number of the cell lines of the present invention. During the telephonic interview, the Examiner indicated that the recitation of the ATCC accession number of the cell lines would obviate the rejection, thus, in light of this amendment, Applicants respectfully request withdrawal of the rejection.

CONCLUSION

Claims 5, 7, 8 and 11 are pending in this application. Claims 5, 7, 8 and 11 have been have been amended without prejudice and acquiescence.

In view of the above, each of the presently pending claims in this application is believed to be in immediate condition for allowance. Accordingly, the Examiner is respectfully requested to withdraw the outstanding rejection of the claims and to pass this application to issue. If there are any outstanding issues, Applicants respectfully request that the undersigned be contact so that these issues may be resolved quickly and this application can proceed to allowance.

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 06-2375, under Order No. 10020885 from which the undersigned is authorized to draw.

Dated: February 13, 2003

Respectfully submitted,

By 

Melissa W. Acosta

Registration No.: 45,872

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100

Houston, Texas 77010-3095

Phone (713)651-5407

Fax (713)651-5246

Appendix A
Version With Markings to Show Changes Made

5. (Amended Twice) A non transgenic mouse mammary adenocarcinoma cell line ~~derived from a murine progestin independent C7 HI tumor, wherein the cell line expresses estrogen and progesterone receptors and the cell line is~~ selected from the group consisting of MC4-L1 (ATCC# PTA-889), MC4-L3 (ATCC# PTA-891), MC4-L2 (ATCC# PTA-892) and MC7-L1 (ATCC # PTA-890)~~MC7 L1 (ATCC # PTA-890).~~

7. (Amended) A non-transgenic mouse mammary adenocarcinoma cell line system for testing the activity of a hormone, an anti-hormone, a pharmacological compound and an environmental agent, wherein the system comprises a cell line selected from the group consisting of a MC4-L1 (ATCC# PTA-889), MC4-L3 (ATCC# PTA-891), MC4-L2 (ATCC# PTA-892) and MC7-L1 (ATCC # PTA-890) cell line.~~MC7 L1 cell line.~~

8. (Amended) An *in vitro* method for testing the activity of a hormone, an anti-hormone, a pharmacological compound or an environmental agent, comprising the steps of:

cultivating a cell line system, wherein the cell line system comprises a cell line selected from the group consisting of MC4-L1 (ATCC# PTA-889), MC4-L3 (ATCC# PTA-891), MC4-L2 (ATCC# PTA-892) and MC7-L1 (ATCC # PTA-890);~~a MC7 L1 cell line derived from a murine progestin independent C7 HI tumor, wherein the cell line expresses estrogen and progesterone receptors;~~

exposing the cell line system to the hormone, the anti-hormone, the pharmacological compound, or the environmental agent; and

quantifying cell proliferation.

11. (Amended Twice) A kit for determining the effect of a hormone, anti-hormone, pharmacological compounds and environmental agents, wherein the kit comprises an aliquot of a cell line selected from the group consisting of MC4-L1 (ATCC# PTA-889), MC4-L3

(ATCC# PTA-891), MC4-L2 (ATCC# PTA-892) and MC7-L1 (ATCC # PTA-890)a MC7-
L1 cell line (ATCC# PTA-890), and a method for evaluating the proliferation of cells.

Appendix B
Claims Pending as of February 13, 2003

5. (Amended Twice) A non transgenic mouse mammary adenocarcinoma cell line-, wherein the cell line is selected from the group consisting of MC4-L1 (ATCC# PTA-889), MC4-L3 (ATCC# PTA-891), MC4-L2 (ATCC# PTA-892) and MC7-L1 (ATCC # PTA-890).
7. (Amended) A non-transgenic mouse mammary adenocarcinoma cell line system for testing the activity of a hormone, an anti-hormone, a pharmacological compound and an environmental agent, wherein the system comprises a cell line selected from the group consisting of MC4-L1 (ATCC# PTA-889), MC4-L3 (ATCC# PTA-891), MC4-L2 (ATCC# PTA-892) and MC7-L1 (ATCC # PTA-890) cell line..
8. (Amended) An *in vitro* method for testing the activity of a hormone, an anti-hormone, a pharmacological compound or an environmental agent, comprising the steps of:
- cultivating a cell line system, wherein the cell line system comprises a cell line selected from the group consisting of MC4-L1 (ATCC# PTA-889), MC4-L3 (ATCC# PTA-891), MC4-L2 (ATCC# PTA-892) and MC7-L1 (ATCC # PTA-890);
- exposing the cell line system to the hormone, the anti-hormone, the pharmacological compound, or the environmental agent; and
- quantifying cell proliferation.
11. (Amended Twice) A kit for determining the effect of a hormone, anti-hormone, pharmacological compounds and environmental agents, wherein the kit comprises an aliquot of a cell line selected from the group consisting of MC4-L1 (ATCC# PTA-889), MC4-L3 (ATCC# PTA-891), MC4-L2 (ATCC# PTA-892) and MC7-L1 (ATCC # PTA-890) and a method for evaluating the proliferation of cells.

ATCC

10801 University Blvd • Manassas, VA 20110-2209 • Telephone: 703-365-2700 • FAX: 703-

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3
AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.2

To: (Name and Address of Depositor or Attorney)

Instituto De Biología Y Medicina Experimental
Attn: Claudia Lanari, Ph.D.
Consejo De Investigaciones Científicas Y Técnicas
Vuelta De Obligado 2490
Buenos Aires, Argentina

Deposited on behalf of: Instituto de Biología y Medicina Experimental, Consejo Nacional de
Investigaciones Científicas y Técnicas (IBYME-CONICET)

Identification Reference by Depositor: " " "

MC4-L1 Cell line
MC7-L1 Cell line
MC4-L3 Cell line
MC4-L2 Cell line

PTA-889
PTA-890
PTA-891
PTA-892

The deposits were accompanied by: a scientific description, a proposed taxonomic description indicated above.
The deposits were received October 28, 1999 by this International Depository Authority and have been accepted.

AT YOUR REQUEST: ☒ We will inform you of requests for the strains for 30 years.

The strains will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strains, and ATCC is instructed by the United States Patent & Trademark Office or the depositor to release said strains.

If the cultures should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace them with living cultures of the same.

The strains will be maintained for a period of at least 30 years from date of deposit, or five years after the most recent request for a sample, whichever is longer. The United States and many other countries are signatory to the Budapest Treaty.

The viability of the cultures cited above was tested November 5, 1999. On that date, the cultures were viable.

International Depository Authority: American Type Culture Collection, Manassas, VA 20110-2209 USA.

Signature of person having authority to represent ATCC:

Barbara M. Hulley
Barbara M. Hulley, Administrator, Patent Depository

Date: November 5, 1999

cc:

Fernando Martin Alonso